SCHEMBL21361404

SCHEMBL21361404

C=C1CN(S(=O)(=O)c2ccc(N(C)C)cc2)CCCN(CC2CCCCC2)CCCN(S(=O)(=O)N2CCc3cccc(Cl)c3C2)C1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CD4 P01730 6/20 0.42
SORT1 Q99523 1/20 0.41
AKR1C3 P42330 2/20 0.40
AKR1C2 P52895 2/20 0.40
AKR1C1 Q04828 1/20 0.40
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTR6 P50406 2/20 0.39
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
DRD2 P14416 1/20 0.35
HRH3 Q9Y5N1 1/20 0.34
TSHR P16473 1/20 0.33
PDE4B Q07343 1/20 0.33
DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23102048 0.95 LMNA (0.45) CD4SORT1AKR1C3AKR1C2AKR1C1
SCHEMBL21361405 0.90 CD4 (0.46) CD4SORT1AKR1C3LMNASMN1; SMN2
SCHEMBL21361403 0.86 CD4 (0.45) CD4SORT1AKR1C3AKR1C1LMNA
SCHEMBL21361406 0.86 CD4 (0.45) CD4SORT1AKR1C3AKR1C1LMNA
SCHEMBL21361494 0.85 CD4 (0.46) CD4SORT1LMNASMN1; SMN2ALDH1A1
SCHEMBL21361540 0.85 LMNA (0.43) AKR1C3AKR1C2LMNASMN1; SMN2ALDH1A1
SCHEMBL21361525 0.84 CD4 (0.44) CD4SORT1LMNASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL21359286 0.84 CD4 (0.48) CD4SORT1LMNASMN1; SMN2ALDH1A1
SCHEMBL23102206 0.84 CD4 (0.43) CD4SORT1LMNAHTR6ALDH1A1
SCHEMBL23102057 0.83 CD4 (0.45) CD4SORT1AKR1C3LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G CD4 3678/4885SORT1 2452/4885AKR1C3 4212/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3727/4885SORT1 2562/4885AKR1C3 4231/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G CD4 3471/4885SORT1 2267/4885AKR1C3 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.